Safety and Efficacy of NK510 to Treat NSCLC

NSCLC Clinical Trial

Official title:

Exploratory Study of NK510 Combined With PD-1 Blockade in the Treatment of Relapsed and Refractory Advanced NSCLC

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06097962
• Other study ID #: NK510-06
• Status: Recruiting
• Phase: Early Phase 1
• Start date: July 1, 2023
• Est. completion date: July 1, 2024

Study information

• Verified date: October 2023
• Source: Base Therapeutics (Shanghai) Co., Ltd.
• Contact: Jun Yan, PhD
• Phone: +86 186 2166 8515
• Email: yanjun[@]basetherapeutics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced NSCLC.NK510 will be administered in combination with PD-1 blockade. Patients are required to undergo a biopsy for confirmation of tumor PD-L1 expression,and EGFR,ROS1,ALK gene must be negative. The safety and efficacy of this treatment will be evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9
• Est. completion date: July 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• age=18 years;

• Epidermal growth factor receptor (EGFR) gene mutation negative, ROS oncogene 1 (ROS1) negative, and anaplastic lymphoma kinase (ALK) negative, stage III or IV non-small cell lung cancer that cannot be operated on or treated with radiotherapy, locally advanced or relapsed or metastatic non-small cell lung cancer;

• Biopsy tissue or pathological sections can be obtained, and tumor PD-L1 expression is positive (defined as = 1% of TPS);

• After receiving = 4 courses of PD-1 monoclonal antibody ± chemotherapy in the past, the disease is currently in a stable or progressive state;

• According to RECIST v1.1 (Solid Tumor Efficacy Evaluation Criteria), there is at least one CT scan measurable lesion present;

• ECOG physical status score of 0-2;

• Expected survival >=3 months;

• Except for hair loss and fatigue, all AE after anti-tumor treatments have alleviated toxicity to level 1 (CTCAE v5.0) or original baseline;

• Female of childbearing age must be non lactating and have a negative serum pregnancy test within 1 week prior to enrollment;

• Voluntarily sign an informed consent form to participate in this study.

Exclusion Criteria:

• Pregnant or lactating female patients;

• Patients with central nervous system metastasis (CNS) and/or cancerous meningitis and obvious symptoms;

• Other malignancies have been diagnosed within 3 years prior to the first use of the study drug;

• Subjects with active, known or suspected autoimmune diseases [excluding type I diabetes, hypothyroidism requiring hormone replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis or alopecia) or diseases that are not expected to recur without external triggers;

• subjects have a history of immune deficiency, including HIV testing positive, or other acquired or congenital immune deficiency diseases or organ transplantation history;

• Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to: severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, third degree atrioventricular block, etc; At rest, the QTc interval obtained from a 12 lead electrocardiogram examination is>480 ms; Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade 3 or above cardiovascular and cerebrovascular events occurred within 6 months prior to enrollment; The New York Heart Association (NYHA) has a heart function rating of = II or a left ventricular ejection fraction (LVEF) of<50%; Clinically uncontrollable hypertension;

• Radical radiotherapy was performed within 4 weeks prior to enrollment; Local palliative radiotherapy or Chinese herbal medicine/traditional Chinese patent medicines and simple preparations with anti-tumor indications within 2 weeks before enrollment;

• Not fully recovered from major surgery or trauma within 2 weeks prior to enrollment;

• Participated in research drug trials and received research treatment or used research instruments within 4 weeks before enrollment;

• Other anti-tumor treatments outside of this research protocol are currently underway or planned;

• Received blood transfusion, erythropoietin, granulocyte colony stimulating factor (G-CSF), or granulocyte macrophage colony stimulating factor treatment within 2 weeks prior to enrollment;

• Subjects who received systemic treatment with corticosteroids (prednisone>10 mg/day or equivalent) or other immunosuppressive/enhancing drugs (such as thymosin, interleukin-2, and interferon) within 2 weeks prior to enrollment. Allowing selected subjects to inhale or topically use corticosteroids in the absence of active autoimmune diseases;

• The virological examination of hepatitis B or hepatitis C during screening meets any of the following criteria:

1. HBsAg positive and peripheral blood HBV-DNA titer detection=1×10^3 copies/mL or upper limit of normal value;

2. HCV antibody positive;

• Subjects who are known to be allergic or intolerant to PD-1 monoclonal antibody.

• Meet any of the following standards:

1. Hematological:Neutrophil count <1.5×10^9/L; Platelet count < 75×10^9/L; Hemoglobin < 9 g/dL;

2. Hepatic:ALT > 3 × ULN (tumor liver metastasis = 5×ULN); AST > 3×ULN (tumor liver metastasis = 5×ULN); TBIL > 1.5 ×ULN or TBIL>2.5 × ULN (3.0 mg/dL) in Gilbert syndrome subjects;

3. Renal:Serum creatinine > 1.5 × ULN or creatinine clearance < 50mL/min;

• Any uncertain factors that affect the safety or compliance of patients.

• Investigators believe that any other serious or uncontrollable medical disease, active infection, abnormal physical examination, laboratory examination, mental state change, or mental illness increases the risk of the subject or affects the research results.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• NSCLC

Intervention

Drug:
• NK510
Intravenous infusion
• Tislelizumab,atezolizumab or sugemalimab
Administer according to the instructions

Locations

Country	Name	City	State
China	General Hospital of Eastern Theater Command	Nanjing	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
Base Therapeutics (Shanghai) Co., Ltd.	The General Hospital of Eastern Theater Command

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-Limiting Toxicity	To evaluate the DLT during N510 treatment	6 weeks
Primary	Maximal Tolerable Dose	to evaluate the MTD of NK510	6 weeks
Secondary	Overall response rate (ORR) after administration	Effectiveness Metrics	6 weeks